source
- Poll Shows Readers Most Excited for PersevERA BC Trial Data at ASCO 2026As the 2026 ASCO Annual Meeting draws near, a recent poll asked oncology readers which breast-cancer abstract they are most looking forward to. Respondents could choose among several late-breaking…
- Capricor sues Nippon Shinyaku over pricing dispute for Duchenne cell therapy candidateCapricor Therapeutics announced it has filed a lawsuit against its Japanese partner Nippon Shinyaku. The suit alleges a flaw in the pricing terms of the distribution and commercialization agreemen…